Phase 2A Open Label Safety Study of Fovista (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Trial Profile

Phase 2A Open Label Safety Study of Fovista (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Pegpleranib (Primary) ; Vascular endothelial growth factors inhibitors
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 05 Aug 2015 According to an Ophthotech media release, interim data from this trial is expected by the end of 2015.
    • 22 May 2015 Planned End Date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top